Barclays analyst Etzer Darout raised the firm’s price target on CytomX Therapeutics (CTMX) to $16 from $10 and keeps an Overweight rating on the shares. The firm believes the CX-2051 updates should alleviate concerns of the early clinical update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics price target raised to $16 from $8 at Jefferies
- CytomX Therapeutics price target raised to $15 from $10 at Guggenheim
- CytomX Therapeutics 45.9M share Secondary priced at $5.30
- Midday Fly By: Nvidia bullish on AI revenue, MasterCard to acquire BVNK
- CytomX Therapeutics price target raised to $11 from $6 at Wedbush